Table 3.
Summary of results per hundred infants from the base case model
| |
Palivizumab |
No prophylaxis |
|
||
|---|---|---|---|---|---|
| Costs | QALYs | Costs | QALYs | ICER | |
| CHD infants |
£636,108 |
2,597 |
£449,120 |
2,591 |
£33,216 |
| CLD infants |
£569,491 |
2,613 |
£440,816 |
2,606 |
£19,168 |
| Preterm infants |
|
|
|
|
|
| <29 wGA |
£367,776 |
2,622.94 |
£354,226 |
2,619.42 |
£3,845 |
| 29-32 wGA |
£353,668 |
2,623.12 |
£272,481 |
2,620.43 |
£30,205 |
| 33-35 wGA | £318,079 | 2,622.90 | £73,621 | 2,620.43 | £99,056 |
Abbreviations: CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, QALY Quality-adjusted life-year, ICER Incremental cost-effectiveness ratio.